The Value Portfolio Fri, May 15, 2020 4 Comments. Alexion completed the acquisition through a tender offer and subsequent merger of Portola with Odyssey Merger Sub Inc., a wholly owned subsidiary of Alexion (“Buyer”). 2, 2020– Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). ALXN2075 (cerdulatinib): Acquired as part of the Portola acquisition, ALXN2075 is a dual spleen tyrosine kinase and janus kinase (SYK/JAK) inhibitor being evaluated in a Phase 1/2a study in patients with relapsed/refractory chronic lymphocytic leukemia or B-cell or T-cell non-Hodgkin lymphoma. The actual amounts will be determined as of the transaction close. BOSTON –(BUSINESS WIRE)–Jul. Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. As part of the acquisition, Alexion will also be acquiring cash currently on Portola's balance sheet, net of debt of approximately $215 million that will become due upon closing. The tender offer for all of the outstanding shares of common stock of Portola at a price of $18.00 per share expired as scheduled, one minute following 11:59 p.m., New … Alexion completed the acquisition through a tender offer and subsequent merger of Portola with Odyssey Merger Sub Inc., a wholly owned subsidiary of Alexion (“Buyer”). Alexion Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. announced today that they have entered into a definitive merger agreement for Alexion to acquire Portola, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. * alexion to acquire portola * alexion pharmaceuticals inc - deal for $18 per share in cash * alexion pharmaceuticals inc - alexion will fund transaction with cash on hand. For Alexion, the acquisition of Portola comes about six months after the company’s board of directors rejected a large stakeholder’s call for a sale. Portola closed Monday at $7.76 per share. As of December 31, 2019, cash and short-term investments were approximately $430 million. The company acquired Portola Pharmaceuticals in July for $1.4 billion, but was strongly opposed by activist investors Elliott Management Corp. Portola markets Andexxa/Ondexxya, the first and only approved Factor Xa inhibitor reversal agent, used to reverse the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding. Alexion completed the acquisition through a tender offer and subsequent merger of Portola with Odyssey Merger Sub Inc., a wholly owned subsidiary of Alexion ("Buyer"). The acquisition will expand Alexion’s … ALXN1820: In January 2021, Alexion initiated a Phase 1 … * alexion to acquire portola * alexion pharmaceuticals inc - deal for $18 per share in cash * alexion pharmaceuticals inc - alexion will fund transaction with cash on hand. –Conference call and webcast scheduled for today, May 5, at 8:00 a.m. ET–. As part of the acquisition, Alexion will also be acquiring cash currently on Portola’s balance sheet, net of debt of approximately $215 million that will become due upon closing. Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops and commercializes drugs. In rejecting the recommendation for a sale, the board of directors pointed … In premarket trading, the stock has risen to nearly $18. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and … Alexion completed the acquisition through a tender offer and subsequent merger of Portola with Odyssey Merger Sub Inc., a wholly owned subsidiary of Alexion (“Buyer”). Alexion Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc.announced that they have entered into a definitive merger agreement for Alexion to acquire Portola, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Alexion said the acquisition of Portola will bolster its commercial portfolio and create long-term value for its shareholders. Headquartered and founded in South San Francisco, California, Portola Pharmaceuticals is a member of the NASDAQ Biotechnology Index. The company focuses primarily on drugs used in the treatment of thrombosis and hematological malignancies. Alexion will be acquiring cash currently on Portola’s balance sheet, net of debt of ~$215M that will become due upon closing. In rejecting the recommendation for a sale, the board of directors pointed … Last week, Alexion inked the $1.4 billion agreement to acquire Portola and its laggard bleeding drug Andexxa, which has delivered disappointing sales since its launch in 2018. Portola’s commercialized medicine, Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya ® in … Under terms of the deal, Alexion will acquire Portola’s stock at $18 per share. Alexion Pharmaceuticals has signed a definitive agreement to acquire Portola Pharmaceuticals for a total consideration of $1.41bn, or $18 per share. Portola closed Monday at $7.76 per share. Portola’s commercialized medicine, Andexxa ® [coagulation factor Xa (recombinant), … Alexion to Acquire Portola; Alexion to Acquire Portola Details Category: More News Published on Tuesday, 05 May 2020 18:49 Hits: 775 – Expands and diversifies Alexion’s hematology, neurology and critical care commercial portfolio with transformative Factor Xa inhibitor reversal agent – – Conference call and webcast scheduled for today, May 5, at 8:00 a.m. Under terms of the deal, Alexion will acquire Portola’s stock at $18 per share. As of December 31, 2019, cash and short-term investments were approximately $430 million. The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." In premarket trading, the stock has risen to nearly $18. In May 2020, Alexion … As part of the acquisition, Alexion will also be acquiring cash currently on Portola’s balance sheet, net of debt of approximately $215 million that will become due upon closing. Alexion: Another Deal, Now Portola. Portola's main drug Andexxa is what's known as a reversal agent for Factor Xa inhibitors, a class of anticoagulant drugs that includes Bristol Myers Squibb and Pfizer's Eliquis as well as Johnson & Johnson and Bayer's Xarelto. Under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola’s common stock at a price of $18 per share in cash. As part of the acquisition, Alexion will also be acquiring cash currently on Portola’s balance sheet, net of debt of approximately $215 million that will become due upon closing. Portola’s commercialized medicine, Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya in Europe, is … Alexion’s CEO, Ludwig Hantson, told investors May 5 that the acquisition immediately diversifies the company’s commercial-stage portfolio by adding Portola’s Andexxa (coagulation factor … Portola is now a wholly owned subsidiary of Alexion. The actual amounts will be determined following the closure of the transaction; The transaction is expected to be closed in Q3’20. Shares of Portola Pharmaceuticals more than doubled in premarket trading on news that Boston-based Alexion Pharmaceuticals is acquiring the company and its blood-disorder assets for $1.41 billion in cash. Data are expected in the first half of 2021. The deal brings Portola’s Andexxa [coagulation factor Xa … Alexion Pharmaceuticals (NASDAQ:ALXN) has completed its acquisition of Portola Pharmaceuticals (NASDAQ:PTLA), through a tender offer and merger with its subsidiary, Odyssey Merger Sub Inc. The tender offer for all of the outstanding shares of common stock of Portola at a price of $18.00 per share expired as scheduled, one minute following 11:59 p.m., New … The tender offer is subject to customary conditions, including the tender of a majority of the outstanding shares of Portola common stock, the expiration or termination of the waiting period under the Hart … The purchase is subject to approval by a majority interest of … Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. The actual amounts will be determined as of the transaction close. The acquisition adds Factor Xa inhibitor reversal agent Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya ® in Europe, to Alexion’s commercial … For Alexion, the acquisition of Portola comes about six months after the company’s board of directors rejected a large stakeholder’s call for a sale. Unlike those earlier three, however, Alexion's acquisition of Portola places the company in a broader, rather than rare disease, market. The tender offer for all of the outstanding shares of common stock of Portola at a price of $18.00 per share expired as scheduled, one minute following 11:59 p.m., New York City time, on July 1, … As of December 31, 2019, cash and short-term investments were approximately $430 million. Alexion to acquire all shares of Portola’s common stock at $18/ share in cash with a premium of 132%. Alexion will also be acquiring $215 million of cash on … As part of the acquisition, Alexion will also be acquiring cash currently on Portola’s balance sheet, net of debt of approximately $215 million that will become due upon closing. ET – BOSTON, MA & SOUTH SAN … The Value Investor Fri, May 08, 2020 11 Comments. Portola is now a wholly owned subsidiary of Alexion. Portola is now a wholly owned subsidiary of Alexion. The actual amounts will be determined as of the transaction close. Portola closed Monday at $7.76 per share. In rejecting the recommendation for a sale, the board of directors pointed … Commenting on Alexion acquisition of Portola, Scott Garland – President and CEO of Portola Pharmaceuticals, said: “In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. When the tender offer is completed, Alexion will buy back all remaining shares not tendered in the offer at the same price of $18 per share through a merger. Under the terms of the agreement, Alexion’s subsidiary will initiate a tender offer to acquire all of the outstanding shares of Portola’s common stock at a price of $18 per share in cash. Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing therapeutics for life-threatening blood disorders. Under terms of the deal, Alexion will acquire Portola’s stock at $18 per share. In premarket trading, the stock has risen to nearly $18. As part of the acquisition, Alexion will also be acquiring cash currently on Portola’s balance sheet, net of debt of approximately $215 million that will become due upon closing. For Alexion, the acquisition of Portola comes about six months after the company’s board of directors rejected a large stakeholder’s call for a sale. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today that they have entered into a definitive merger agreement for Alexion to acquire Portola, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Alexion Pharmaceuticals Inc., of Boston, will diversify its portfolio beyond its top-selling Soliris (eculizumab) and C5 inhibitor Ultomiris (ravulizumab) by acquiring Portola Pharmaceuticals Inc. for $1.4 billion. Alexion To Acquire Portola - What That Means.